Using MHC scores that reflect both the fraction of tumor cells expressing the marker and the level of expression, we found that intact expression of the MHC-I and MHC-II molecules on tumor cells was strongly associated with response to anti-PD-1 monotherapy, but was not required for response to combination immunotherapy. This evidence concerns the gene HLA-C and neoplasm.